reference/30494013

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30494013

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Research Support, Non-U.S. Gov't
issn	2059-7029
issueIdentifier	2
pageRange	100093-
publicationName	ESMO Open
startingPage	100093
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_00065a2f9954e45597f8af2a6ce21fc2
bibliographicCitation	Takahashi T, Yamazaki K, Oki E, Shiozawa M, Mitsugi K, Makiyama A, Nakamura M, Ojima H, Kagawa Y, Matsuhashi N, Okuda H, Asayama M, Yuasa Y, Shimada Y, Manaka D, Watanabe J, Oba K, Yoshino T, Yoshida K, Maehara Y. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. ESMO Open. 2021 Apr;6(2):100093. doi: 10.1016/j.esmoop.2021.100093.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_98b291c55c6a1363f55c85257e6cc8f9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_62aff53b9cb87203f0544ea651071044 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8a4b901e4b29a83ece0cca59d7bd341e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e4285d880003ea361b5d4ed2097f8647 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2b5a8923f90a8a1ff850771aab9cc9e2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c68facf26a0e5fc0e6d671be45502062 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_71566a9daf5100daab7503b7f6723a0b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e879c9c6649ae18d121665f3556251c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_532a98ff2e01fd64518abf69c6390df0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a3edc45f0d459dee30139898716a1b67 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_38d5f081dfc909a0b78c0f2171f73215 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_850b0b06a17e70ecd0e8c4b139ccbdb3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d3f3d7fb823b10a738e9e49dc7cd1b9b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_389a53dca35d78df381df8774954af89 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bfc55c8c74318430ca0777fded79c0bc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ce034c58ad9de125a383d3a2551b5c2f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_485144751034e5ef5ebac6737a6dc763 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7b80aa05868e5d3e8a3a602a0c801087 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e81a69b318817e6f3fcf8e4a2c2ff2f4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3867c8f7d527672cc7cbb14856e9c347
date	202104
identifier	https://doi.org/10.1016/j.esmoop.2021.100093 https://pubmed.ncbi.nlm.nih.gov/33744811 https://pubmed.ncbi.nlm.nih.gov/PMC7985393
isPartOf	https://portal.issn.org/resource/ISSN/2059-7029 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/45648
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7
discusses	http://id.nlm.nih.gov/mesh/M0021455 http://id.nlm.nih.gov/mesh/M0021960 http://id.nlm.nih.gov/mesh/M0018277 http://id.nlm.nih.gov/mesh/M000626008 http://id.nlm.nih.gov/mesh/M0443627
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D015179Q000235 http://id.nlm.nih.gov/mesh/D014271Q000627 http://id.nlm.nih.gov/mesh/D015179Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D011759 http://id.nlm.nih.gov/mesh/D000068258Q000627 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D013941 http://id.nlm.nih.gov/mesh/D009154 http://id.nlm.nih.gov/mesh/D006801
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6323266 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6256 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9672 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11167602 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_304854e2e79de0f96dc5477fef38a18f

Showing number of triples: 1 to 59 of 59.